Tetra Therapeutics Initiates Phase 2b/3 Clinical Studies of Investigational Drug BPN14770 in Fragile X Syndrome | Small Molecules

Tetra Therapeutics Initiates Phase 2b/3 Clinical Studies of Investigational Drug BPN14770 in Fragile X Syndrome

Related Keywords

Japan ,Osaka ,United States ,Grand Rapids ,Michigan ,Illinois ,Rush University Medical Center ,Chicago ,Elizabethm Berry Kravis ,Elizabeth Berry Kravis ,Shionogi Co Ltd ,Drug Agency ,Drug Administration ,Shionogi Group Company ,Tetra Therapeutics Initiates Phase ,Investigational Drug ,Fragilex Syndrome ,United Statesi July ,Tetra Therapeutics ,Orphan Drug Designation ,Chad Coberly ,Chief Executive Officer ,Small Molecule ,New Chemical Entity ,Ice ,Chemistry ,Mural ,Inhaled ,Drug Delivery ,Depot ,Flow Release ,